MolMed SpA (MLM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:MolMed SpA (MLM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7605
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MolMed SpA (Molmed) is a biotechnology company which offers research, development, manufacturing and clinical validation of novel anticancer therapies. Its pipeline antitumour products include Zalmoxis (TK), a cell based therapy enabling bone marrow transplants donors for the treatment of high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis, inducing a rapid immune reconstitution; NGR-hTNF, a therapeutic agent showing anti-tumor activity for solid tumors; and CAR-CD44v6, an immuno-gene therapy project for haematological malignancies and several epithelial tumours. The company also conducts cell and gene therapy projects such as development and the validation of the manufacturing process and control strategy, cGMP production of clinical-grade viral vectors and manufacturing of patient-specific genetically engineered cells. Molmed is headquartered in Milano, Italy.

MolMed SpA (MLM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MolMed SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MolMed SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
MolMed SpA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
MolMed Acquires CAR-CD44v6 Project from San Raffaele Hospital 11
Partnerships 12
MolMed Enters into Development Agreement with GlaxoSmithKline 12
MolMed and AbCheck Enter into Agreement 13
Orchard Therapeutics and MolMed Expand Collaboration Agreement 14
MolMed and Cellectis Enter into Co-Development Agreement 15
MolMed Enters into Agreement with Rocket Pharma 16
MolMed Enters into Co-Development Agreement with Genenta Science 17
MolMed Enters into Agreement with GlaxoSmithKline 18
Licensing Agreements 19
MolMed and Dompe Expand Licensing and Distribution Agreement 19
TTY Biopharm Enters into Licensing Agreement with MolMed 20
Megapharm Enters into Licensing Agreement with MolMed for Zalmoxis 21
Oxford BioMedica Enters into Licensing Agreement with MolMed 22
Equity Offering 23
Molmed Raises USD3.6 Million in Fifth Tranche of Private Placement of Shares 23
MolMed Raises USD6.2 Million in Fourth Tranche of Private Placement of Shares 25
MolMed Raises USD2.2 Million in Second Tranche of Private Placement of Shares 27
MolMed SpA – Key Competitors 28
MolMed SpA – Key Employees 29
MolMed SpA – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Jul 30, 2018: MolMed approves results at June 30th 2018 31
May 11, 2018: MolMed approves first quarter 2018 results, significantly improved compared to the first quarter 2017 33
Apr 12, 2018: MolMed: the Shareholders’ Meeting approves 2017 Financial Statements 35
Mar 09, 2018: MolMed: Full Year 2017 Results 36
Nov 06, 2017: The Board of Directors Examined the Business Performance and Approved the First Nine Months Financial Report at September 30th, 2017 39
Nov 06, 2017: MolMed Board of Directors examined the business performance and approved the first nine months financial report ended at September 30th, 2017 43
Jul 27, 2017: MolMed Board of Directors reviewed business performance and approved the first half-year financial report ended June 30th, 2017 47
May 08, 2017: MolMed’s Board of Directors reviewed business performance and approved Interim Results at March 31st, 2017 51
Mar 06, 2017: MolMed’s Board of Directors reviewed the business performance and approved the draft financial statements for FY 2016 53
Corporate Communications 57
Sep 24, 2018: MolMed: Carlo Incerti succeeds to Claudio Bordignon as chairman of the board. Salvatore Calabrese appointed officer responsible for the preparation of corporate financial reports 57
Sep 11, 2018: MolMed names Mr. Salvatore Calabrese Chief Financial Officer 59
Jun 29, 2018: MolMed: resignation of the Officer Responsible for the preparation of corporate financial reports 60
Product Approvals 61
Jun 01, 2017: MolMed provides update on Zafiride Conditional Marketing Authorization application 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
MolMed SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MolMed SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MolMed SpA, Deals By Therapy Area, 2012 to YTD 2018 9
MolMed SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
MolMed Acquires CAR-CD44v6 Project from San Raffaele Hospital 11
MolMed Enters into Development Agreement with GlaxoSmithKline 12
MolMed and AbCheck Enter into Agreement 13
Orchard Therapeutics and MolMed Expand Collaboration Agreement 14
MolMed and Cellectis Enter into Co-Development Agreement 15
MolMed Enters into Agreement with Rocket Pharma 16
MolMed Enters into Co-Development Agreement with Genenta Science 17
MolMed Enters into Agreement with GlaxoSmithKline 18
MolMed and Dompe Expand Licensing and Distribution Agreement 19
TTY Biopharm Enters into Licensing Agreement with MolMed 20
Megapharm Enters into Licensing Agreement with MolMed for Zalmoxis 21
Oxford BioMedica Enters into Licensing Agreement with MolMed 22
Molmed Raises USD3.6 Million in Fifth Tranche of Private Placement of Shares 23
MolMed Raises USD6.2 Million in Fourth Tranche of Private Placement of Shares 25
MolMed Raises USD2.2 Million in Second Tranche of Private Placement of Shares 27
MolMed SpA, Key Competitors 28
MolMed SpA, Key Employees 29
MolMed SpA, Other Locations 30

List of Figures
MolMed SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MolMed SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[MolMed SpA (MLM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • LookingGlass Cyber Solutions Inc:企業の戦略的SWOT分析
    LookingGlass Cyber Solutions Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Compagnie Des Alpes Sa:企業の戦略・SWOT・財務分析
    Compagnie Des Alpes Sa - Strategy, SWOT and Corporate Finance Report Summary Compagnie Des Alpes Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Service Corporation International (SCI):企業の財務・戦略的SWOT分析
    Service Corporation International (SCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Sensient Technologies Corp (SXT):企業の財務・戦略的SWOT分析
    Sensient Technologies Corp (SXT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • City National Wealth Management:企業の戦略・SWOT・財務分析
    City National Wealth Management - Strategy, SWOT and Corporate Finance Report Summary City National Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Aarti Drugs Ltd (AARTIDRUGS):企業の財務・戦略的SWOT分析
    Summary Aarti Drugs Ltd (ADL), is a contract manufacturer of pharmaceutical products that offers therapeutic products, ingredients, bulk drugs, and chemicals. The company's products include active pharmaceutical ingredients, pharma intermediates, and specialty chemicals. Its active pharmaceutical in …
  • AutoZone Inc (AZO):企業の財務・戦略的SWOT分析
    AutoZone Inc (AZO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • SVB Financial Group:企業のM&A・事業提携・投資動向
    SVB Financial Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SVB Financial Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Leukocare AG-製薬・医療分野:企業M&A・提携分析
    Summary Leukocare AG (Leukocare) is a clinical stage biotechnology company that offers technologies for stabilizing proteins to increase shelf-life and to facilitate terminal sterilization by irradiation or gas. The company offers services such as development of individual SPS formulations meeting i …
  • Bank Of The Philippine Islands:企業の戦略・SWOT・財務分析
    Bank Of The Philippine Islands - Strategy, SWOT and Corporate Finance Report Summary Bank Of The Philippine Islands - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Plenus Company Limited:企業の戦略・SWOT・財務分析
    Plenus Company Limited - Strategy, SWOT and Corporate Finance Report Summary Plenus Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • NICO Life Insurance Co Ltd:企業の戦略的SWOT分析
    NICO Life Insurance Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Esterline Technologies Corporation:企業のM&A・事業提携・投資動向
    Esterline Technologies Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Esterline Technologies Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析
    RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Alfred E. Tiefenbacher (GmbH & Co KG)-製薬・医療分野:企業M&A・提携分析
    Summary Alfred E. Tiefenbacher (GmbH & Co KG) (AET) is a healthcare products provider that develops active pharmaceuticals ingredients. The company’s products comprise cytotoxic drugs, hormones, OTC drugs, controlled drugs, herbal drugs, high potent drugs, new combination products, inhaler technolog …
  • Cardiva Medical Inc:企業の戦略的SWOT分析
    Cardiva Medical Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Paratek Pharmaceuticals Inc (PRTK):企業の財務・戦略的SWOT分析
    Paratek Pharmaceuticals Inc (PRTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Ricoh Imaging Co Ltd:企業の戦略的SWOT分析
    Ricoh Imaging Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Orange Belgium (OBEL):企業の戦略的SWOT分析
    Orange Belgium (OBEL) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • ChemImage Corp:企業の製品パイプライン分析
    Summary ChemImage Corp (ChemImage) is a molecular chemical imaging company that provides hyperspectral imaging technologies. The company develops molecular chemical imaging devices and data fusion tools for anatomic structure imaging, cancer detection and cardiovascular health assessment. It offers …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆